ARV-trial.com SURVEYOR-II study – Part 3: glecaprevir/pibrentasvir + RBV in genotype 3 with treatment experience and/or cirrhosis Design Randomisation.

Slides:

Advertisements

Similar presentations

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

Advertisements

OBV/PTV/r Placebo Randomisation** 2 : years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.

ALLY-3  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI DCV 60 mg qd + SOF 400 mg qd Not randomised Open-label ALLY-3 Study: DCV + SOF for.

No randomisation Open-label years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

No HBV or HIV co-infection

No cirrhosis or compensated cirrhosis * No HBV or HIV coinfection

W12 N = 126 C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Randomisation * 1:1  Design  Treatment regimens –Co-formulated.

ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.

eGFR (MDRD) > 50 mL/min

Design Randomisation * 1 : 1 Open-label W16 W24 > 18 years

Design Randomisation 1 : 1 Double-blind W8 W12

Design Single arm Open label W12 ≥ 18 years, HCV genotype 1 to 6

No HBV or HIV co-infection

No HBV or HIV co-infection

Phase 3 Treatment-Naïve and Treatment-Experienced

TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1

C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis

Design No randomisation Open-label W12 W years HCV genotype 1

PHOTON-2 Study: SOF + RBV in HCV-HIV co-infection

> 18 years Chronic HCV infection Compensated cirrhosis **

ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.

Compensated cirrhosis No HBV or HIV co-infection

Design Randomisation 2 : 1 Double-blind W12 ≥ 18 years, HCV genotype 3

No HBV or HIV co-infection

GEODE-II Study: OBV/PTV/r + DSV + low dose RBV in genotype 1a

GARNET Study: OBV/PTV/r + DSV 8 weeks in genotype 1b

Retreatment study: SOF/VEL + RBV in prior NS5A failure - Phase II

No cirrhosis or compensated cirrhosis** No HBV or HIV co-infection

AL study: AL ODV + SMV in naïve patients, phase II

Creatinine clearance ≥ 50 ml/min No HBV or HIV co-infection

Design Randomisation* 1 : 1 Open-label W12

Failure to achieve SVR on No HBV or HIV co-infection

ARV-trial.com RUBY-I Study, cohort 2: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for HCV genotype 1 with renal impairment Design Open label W12.

QUARTZ II-III : OBV/PTV/r + SOF RBV in genotype 2 or 3

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

LDV/SOF in kidney transplant recipients

C-BREEZE-2 Study: ruzasvir + uprifosbuvir for 12 weeks in genotype 1-6

Design W12 W16 Randomisation Open-label ≥ 18 years HCV genotype 1 or 4

Design Randomisation* 1 : 1 Double blind W12

SOF/VEL + GS-9857 in genotypes 1-6 Phase II

LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1

ARV-trial.com SURVEYOR-II study – Part 3: glecaprevir/pibrentasvir ± RBV in genotype 3 with treatment experience and/or cirrhosis Design Randomisation.

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced

Design W12 Randomisation * Open-label

ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.

GS-US Study: SOF/VEL + GS-9857 in genotype 1 - Phase II

GS-US Study: SOF/VEL + GS in genotype 2, 3, 4 or 6 - Phase II

LEPTON Study: SOF/VEL + GS-9857 genotype 1 or 3 Phase II

EXPEDITION-V Study: GLE/PIB in patients with renal impairment

ARV-trial.com TURQUOISE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for HCV in HIV co-infected patients Randomisation 1 : 1 Open-label.

ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients

MAGELLAN-3 Study: GLE/PIB + SOF + RBV in patients who failed GLE/PIB

LDV/SOF ± RBV in genotype 3 or 6 – Phase 2

COMMIT Study: SMV + DCV in genotype 1b

ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.

No HBV or HIV co-infection

SOF/VEL in liver transplantation with genotype 1-4 infection

Design W12 W16 Randomisation Open-label ≥ 18 years HCV genotype 1 or 4

Phase 3 Treatment-Naïve and Treatment-Experienced

SOF/VEL ± RBV in genotype 3 with compensated cirrhosis

CONCERTO-4 Study: SMV + PEG-IFNa-2b + RBV for genotype 1

Phase 3 Treatment-Naïve and Treatment-Experienced

ENDURANCE-4 Study: glecaprevir/pibrentasvir in genotype 4, 5 or 6

ARV-trial.com CORAL-I study cohorts 3 to 6: OBV/PTV/r + DSV + RBV in transplant recipients and genotype 1 or 4 Design W12 W24 No randomisation Open-label.

Sequencing cohorts Open-label Design W8 W12 ≥ 18 years

Design W12 Open-label Liver transplant recipients

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

Presentation transcript:

ARV-trial.com SURVEYOR-II study – Part 3: glecaprevir/pibrentasvir + RBV in genotype 3 with treatment experience and/or cirrhosis Design Randomisation Open-label W12 W16 N = 22 GLE/PIB ≥ 18 years HCV genotype 3 HCV RNA > 1000 IU/mL Naïve or treatment-experienced with IFN/PEG-IFN + RBV or SOF + RBV + PEG-IFN Compensated cirrhosis allowed No HBV or HIV co-infection Treatment-experienced with no cirrhosis N = 22 GLE/PIB No randomisation Open-label Naive N = 40 GLE/PIB Cirrhosis GLE/PIB Experienced N = 47 GLE/PIB: 100/40 mg 3 tablets QD Objective SVR12 (HCV RNA < 25 IU/mL), no formal statistical hypothesis SURVEYOR-II – Part 3 Wyles D. Hepatology 2017 (epub ahead of print) 1

Baseline characteristics ARV-trial.com SURVEYOR-II study – Part 3: glecaprevir/pibrentasvir + RBV in genotype 3 with treatment experience and/or cirrhosis Baseline characteristics No cirrhosis, treatment-experienced Randomisation 1 : 1 Cirrhosis No randomisation GLE/PIB 12 weeks N = 22 16 weeks Naïve N = 40 Treatment-experienced N = 47 Median age, years 56 59 Female, % 36 40 23 Race : white, % 77 91 93 89 Mean BMI, kg/m2 26 28 29 27 Median HCV RNA, log10 IU/mL 6.6 6.1 6.2 6.5 Fibrosis stage : F0-F1 / F2 / F3 / F4, % 50 / 18 / 32 / 0 68 / 9 / 23 / 0 0 / 0 / 0 / 100 Treatment-experienced, % IFN/PEG-IFN + RBV SOF + RBV + PEG-IFN 100 64 36 41 47 53 SURVEYOR-II – Part 3 Wyles D. Hepatology 2017 (epub ahead of print) 2

Treatment-experienced Treatment-experienced Treatment-experienced SURVEYOR-II study – Part 3: glecaprevir/pibrentasvir + RBV in genotype 3 with treatment experience and/or cirrhosis SVR12 % 98 100 95 96 91 80 60 40 1:1 randomized 20 22 22 40 47 N= 12 weeks No cirrhosis Treatment-experienced 16 weeks No cirrhosis Treatment-experienced 12 weeks Cirrhosis Treatment-naive 16 weeks Cirrhosis Treatment-experienced Breakthrough Relapse Lost to follow-up 2 1 1 1 SURVEYOR-II – Part 3 Wyles D. Hepatology 2017 (epub ahead of print)

SURVEYOR-II study – Part 3: glecaprevir/pibrentasvir + RBV in genotype 3 with treatment experience and/or cirrhosis Virologic failures 1 2 3 4 5 Type of failure Relapse Breakthrough GLE/PIB duration 12W 16W Treatment-experienced Yes Fibrosis stage F2 F0-F1 F4 Compensated cirrhosis No Baseline HCV RNA, IU/mL 8.1 M 15.7 M 18.9 M 2.8 M 17.4 M Treatment compliance NA NS3 RAVs * at baseline at failure None Y56H + Q168R A166S A156G + A166S NS5A RAVs * Y93H A30K A30K + Y93H L31F + Y93H * RAVs detected by next-generation sequencing at 15% threshold: NS3 : 36, 43, 54, 55, 56, 80, 155, 156, 166, and 168 NS5A : 24, 28, 29, 30, 31, 32, 58, 92, and 93 SURVEYOR-II – Part 3 Wyles D. Hepatology 2017 (epub ahead of print)

Adverse events and laboratory abnormalities ARV-trial.com SURVEYOR-II study – Part 3: glecaprevir/pibrentasvir + RBV in genotype 3 with treatment experience and/or cirrhosis Adverse events and laboratory abnormalities No cirrhosis, treatment-experienced Randomisation 1 : 1 Cirrhosis No randomisation GLE/PIB 12 weeks N = 22 16 weeks Naïve N = 40 Treatment-experienced N = 47 Serious adverse event, N * 1 3 AE leading to discontinuation, N Adverse event in ≥ 10% of patients, % Fatigue Headache 18 23 18 13 25 34 Laboratory abnormalities, N AST grade 3 (> 5 x ULN) Total bilirubin grade 3 (> 3 x ULN) 2 0 0 * Umbilical hernia, colon cancer, pleural effusion, squamous cell carcinoma of the skin, schizophrenia, angina pectoris SURVEYOR-II – Part 3 Wyles D. Hepatology 2017 (epub ahead of print) 5

ARV-trial.com SURVEYOR-II study – Part 3: glecaprevir/pibrentasvir + RBV in genotype 3 with treatment experience and/or cirrhosis Summary High efficacy with GLE/PIB in patients with HCV genotype 3 infection with compensated cirrhosis and/or prior treatment experience SVR12 rates of 98% and 96% in treatment-naïve and treatment- experienced patients with cirrhosis following 12 and 16 weeks of the QD combination, respectively SVR12 rate of 96% in treatment-experienced patients without cirrhosis following 16 weeks of treatment, or 91% after 12 weeks GLE/PIB was well tolerated with mostly mild adverse events no drug related-related serious adverse event few occurrences of grade 3 or higher laboratory abnormalities and no study drug discontinuation SURVEYOR-II – Part 3 Wyles D. Hepatology 2017 (epub ahead of print) 6